Axsome Therapeutics
AXSM
175 hedge funds and large institutions have $794M invested in Axsome Therapeutics in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 41 increasing their positions, 63 reducing their positions, and 22 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
46% more call options, than puts
Call options by funds: $94.9M | Put options by funds: $64.8M
45% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 22
13% more capital invested
Capital invested by funds: $704M → $794M (+$89.5M)
5% more funds holding
Funds holding: 167 → 175 (+8)
0.28% more ownership
Funds ownership: 49.47% → 49.75% (+0.28%)
35% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$23.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.1M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$5.63M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.82M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$3.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$11.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.48M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$3.76M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.6M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$3.4M |
AXSM Hedge Fund Activity: Q1 2022 in Review
175 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2022, worth a combined $794M — up 13% from $704M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AXSM positions and 22 closed out — a net gain of 10 holders — while 41 added to existing stakes and 63 trimmed.
The largest buyer was Fairmount Funds Management, adding an estimated $23.4M. The largest seller was Jane Street, cutting an estimated $11.1M.
- 175 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2022, up from 167 in Q4 2021.
- Funds reported $794M of Axsome Therapeutics stock for Q1 2022, up 13% quarter-over-quarter.
- 32 funds opened new Axsome Therapeutics positions in Q1 2022 and 22 closed out, a net change of +10 holders.
- The largest Axsome Therapeutics buyer in Q1 2022 was Fairmount Funds Management, an estimated $23.4M added.
- The largest Axsome Therapeutics seller in Q1 2022 was Jane Street, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2022.